PURMX Therapeutics
PrivateLast Round
Series A
Extension
Nov 30, 2023
Est. Valuation
$14.38M
Total Funding Raised
$7.8M
Company Overview
PURMX Therapeutics is a biotechnology company that develops innovative RNA-based nucleic acid medicines for the treatment of intractable diseases and cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PURMX Therapeutics Comparables
Compare PURMX Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| e-NA Biotec Inc. | 81% | |
| Novartis | 76% | |
| ANRis, Inc. | 73% |
PURMX Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 30, 2023 | ||||
| Series A | May 31, 2022 |
Key People
Founding team and executive leadership
PURMX Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Keio Innovation Initiative | Series A Extension |
| UTEC (The University of Tokyo Edge Capital Partners) | Series A |
| QB Capital | Series A |
| Mitsubishi UFJ Capital | Series A |
| Hiroshima Venture Capital | Series A |
| Yokohama Capital Co., Ltd. | Series A Extension |
| Osaka University Venture Capital Co., Ltd. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 24, 2025
Grew 50% QoQ from 6 to 9 employees.
- Feb 24, 2025
Grew 80% QoQ, from 5 to 9 employees.
Recent news
Latest coverage and updates
- is_developingSep 29, 2026
PURMX is developing oligonucleotide therapeutics based on naturally occurring microRNAs as active pharmaceutical ingredients and is evaluating their delivery with Nippon Shokubai’s Fol-Dab8 DDS material on Sep 29th '26.
PURMX Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about PURMX Therapeutics's valuation, stock price, and market status.
Is PURMX Therapeutics a public or private company?
PURMX Therapeutics is a private company.
What is the current stock price of PURMX Therapeutics?
PURMX Therapeutics is a private company, so its shares have no public market price. Caplight tracks PURMX Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PURMX Therapeutics worth (valuation)?
PURMX Therapeutics's valuation is estimated at $14.4M based on funding round data.
Can I buy PURMX Therapeutics stock?
PURMX Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PURMX Therapeutics's last funding round?
PURMX Therapeutics's most recent funding round was Series A Extension on November 30, 2023.
Who are the main investors in PURMX Therapeutics?
Key investors in PURMX Therapeutics include UTEC (The University of Tokyo Edge Capital Partners).
Will PURMX Therapeutics IPO soon?
No public IPO plans have been announced for PURMX Therapeutics.
How can I track PURMX Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in PURMX Therapeutics's shares on secondary markets.